2nd iPSC Manufacturing Summit

Memo

With the recent announcement of Fate Therapeutic's preclinical and clinical success with iPSC-derived candidates, the race to streamline iPSC process development is on. Join the 2nd iPSC Manufacturing Summit, the industry-defining forum for technical leaders within manufacturing, process development, quality and regulations. Showcasing in-depth data-driven case studies to accelerate the development of high-quality iPSC lines, with optimized differentiation and automated scale up. This meeting boasts the unique opportunity to discuss the procedural barriers preventing iPSC-derived therapies reaching the clinic, tackling all your CMC and regulatory needs. Take home creative approaches to unify your manufacturing process and advance the quality and quantity of your product for successful commercialization. URLs: Tickets: https://go.evvnt.com/1487104-2?pid=5569 Brochure: https://go.evvnt.com/1487104-3?pid=5569  Date and Time: On Tue, 02 May 2023 08:30 - Thu, 04 May 2023 16:15 Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Drug Developer Pricing - Conference + 3 Workshops: USD 4946.00,Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,Drug Developer Pricing - Conference Only: USD 2999.00,Solution Provider Pricing - Conference + 3 Workshops: USD 6046.00,Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,Solution Provider Pricing - Conference Only: USD 3799.00,Academic Pricing - Conference + 3 Workshops: USD 4246.00,Academic Pricing - Conference + 1 Workshop: USD 3148.00,Academic Pricing - Conference Only: USD 2599.00 Speakers: Allen Feng, Chief Scientific Officer, HebeCell, Anne Plant, Fellow and Chief of Biomaterials and Biosystems, NIST, Anthony Asmar, Biologist, NIST, Brianna Kalicharan, Director, Manufacturing, Vita Therapeutics, Bruno Marques, Head of Process Development, Century Therapeutics, Byeongtaek Oh, Associate Director, Regulatory Affairs, BlueRock Therapeutics, Calvin Chan, Director, Allogeneic Cell Therapy Process Platform, BMS, Craig Beasley, Chief Technology Officer, BlueRock Therapeutics, Dhruv Sareem, Executive Director, Cedars-Sinai Biomanufacturing Center, Eric Law, Head of CMC Regulatory Affairs, Century Therapeutics, Ethan Law, Scientist, Mayo Clinic, Francis Galaway, Senior Quality Assessor, MHRA, Kelly O'Neill, Senior Associate Engineer, Century Therapeutics, Kim Raineri, Chief Technology Officer, Aspen Neuroscience, Mamad Khazaei, Chief Scientific Officer, Inteligex, Mandy Xie, Executive Director, Head of Cell Therapy Product and Analytical Development, BMS, Mia Wang, Senior Director, CMC Cell Therapy Platform, Sana Biotechnology, Mitja Scholz, Vice President, Supply Chain and CMC Strategy, BlueRock Therapeutics, Peter Andersen, Co-Founder and Chief Scientific Officer, Vita Therapeutics, Richard Wang, Chief Executive Officer, Neukio Biotherapeutic, Ruchi Sharma, Scientist, National Eye Institute (NIH), Steven Howe, Senior Director, Cell and Gene Therapy Product Development, GSK, Takehiko Kaneko, Chief Medical Officer, Heartseed Inc, Tomoko Iwata, Principal Scientist, Takeda, Wonjong Si, Associate Director, Cell Therapy Platform Process, Bayer, Ying He, Director, Molecular and Cellular Genomics, Allogene Therapeutics, Zhu Pirot, Analytical Lead, Cell and Gene Therapy Platform, Bayer